Bayer HealthCare AG is subsidiary of Bayer AG group, which has three major sub-groups-Bayer HealthCare, Bayer CropScience and Bayer Material Science. Bayer HealthCare AG has further four divisions – Animal Health, Consumer Care, Medical Care and Pharmaceuticals. Pharmaceutical Division is the largest entity of Bayer HealthCare and is known as Bayer Pharma AG and employs nearly 38000 employees worldwide and contributes to approx. €11 billion in annual revenue.
Bayer AG is a Global Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. Since 2003, Bayer AG acts as a holding company of Bayer Group of companies.
- In Dec 2020, Bayer and Atara Biotherapeutics signed an exclusive worldwide license agreement for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. The agreement includes the development candidate ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors. Under the terms, Atara will receive an upfront payment of USD 60 Mn and is eligible to receive up to USD 610 Mn on achievement of certain development, regulatory and commercialization milestones, as well as tiered royalties up to low double-digit percentage of net sales. As part of the transaction, Atara will also provide translational and clinical manufacturing services to be reimbursed by Bayer.
- In Oct 2020, Vincera Pharma, Inc., in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer. Additionally, Vincera acquire preclinical assets include: VIP236, a small molecule drug conjugate (SMDC) targeting advanced and metastatic cancer; as well as VIP943 (formerly BAY-943) and VIP924 (formerly BAY-924), two antibody-drug conjugates (ADC) targeting hematologic tumors; and VIP217, an oral PTEFb/CDK9 inhibitor in discovery. Financial details remains undisclosed.
- In Sep 2020, Bayer acquired an exclusive global license of ERSO™, a compound in pre-clinical development for metastatic Estrogen Receptor (ER) positive, breast cancer from Systems Oncology, LLC. ERSO is a small molecule activator of the Unfolded Protein Response (UPR) in ER-positive breast cancer cells. Under the terms, Systems Oncology received an upfront of $25 Mn USD and is eligible to receive upto $345 Mn US dollars payments from Bayer upon achievement of certain development, and commercialization milestones, as well as royalties on future global net sales.
- In Feb 2019, Bayer obtained full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195). Both compounds are designed for the treatment of adult and pediatric patients with advanced solid tumors harboring NTRK gene fusions. The option was triggered by the acquisition of Loxo Oncology by Eli Lilly and Company.
- In Jun 2019, Bayer and Arvinas, Inc. (Nasdaq: ARVN), signed an agreement to leverage Arvinas’ novel PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, gynecological diseases and for agricultural applications. Under the terms, Bayer invested $110 Mn in upfront cash and committed funding for the human disease collaboration, the agricultural joint venture, and a direct equity investment by Bayer in Arvinas.
- In July 2015, Bayer acquired development and commercialization rights of an early-stage inhibitor program targeting tumor metabolism for therapeutics and diagnostics purpose from Sprint Biosciences AB. Under the terms, Sprint Bioscience is eligible to receive up to approx. 190 Mn Euro in potential preclinical, clinical and net sales based milestone payments, including an upfront payment.
- In Aug 2013, Compugen and Bayer entered into a research collaboration to develop antibody-based therapeutics for cancer immunotherapy. Under the agreement both companies jointly pursue a preclinical research program and subsequently, Bayer will have further development and worldwide commercialization rights for the drug candidate.
- In 2011, Bayer entered into an agreement with Onyx Pharmaceuticals for the global development and marketing of Regorafenib/Stivarga®. Onyx to receive a royalty on any future global net sales of regorafenib in oncology.
- In 2009, Bayer in-licensed Alpharadin™, an alpha-emmitting radiopharmaceutical, from Algeta, to jointly co-develop and market.
Page 2 of 3
